hero image
Dr. Christopher Paige - University Health Network. Toronto, ON, CA

Dr. Christopher Paige Dr. Christopher Paige

Vice President - Research | University Health Network

Toronto, ON, CANADA

An internationally recognized leader in the area of lymphocyte development and antibody formation

Media

Publications:

Dr. Christopher Paige Publication

Documents:

Photos:

loading image loading image loading image

Audio:

Biography

Dr. Paige earned a Ph.D. in Immunology at the Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences in 1979. He became a Member of the Basel Institute for Immunology in Switzerland where he worked from 1980-1987 before joining the Ontario Cancer Institute as a Senior Scientist in 1987. In 1990, Dr. Paige became the founding Director of the Arthritis and Autoimmunity Research Centre as well as Director of Research at The Wellesley Hospital. In 1998, he returned to the Ontario Cancer Institute to assume the role of Vice President, Research and, subsequently assumed his current position of Vice President, Research at the University Health Network, which comprises four hospitals: Toronto Rehab, Toronto General Hospital, Toronto Western Hospital and Princess Margaret Cancer Centre.

Dr. Paige is a Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto. He is an active educator in the undergraduate, graduate and postgraduate programs of the University’s School of Medicine. He is an internationally recognized leader in the area of lymphocyte development and antibody formation, with an active research program in training the immune system to recognize cancer cells.

He has served on the Research Advisory Boards of the National Cancer Institute and the Arthritis Society of Canada. He is the past Chairman of the Board of the Biotechnology Commercialization Centre which helped establish a Toronto Biotechnology Incubator and past Chairman of BioDiscovery Toronto, a consortium of 12 Toronto-based hospitals and universities engaged in the commercialization of research discoveries. He also serves on the Boards of the Terry Fox Research Institute, The Princess Margaret Cancer Foundation, Toronto General & Western Hospital Foundation, Arthritis Research Foundation, Council of Ontario Research Directors, and the Ontario Health Research Alliance. Dr. Paige is also a co-founder and Chairman of the Board of GEMMA Biotechnology. Its purpose is to discover and commercially develop biological response modifiers which influence the course of human disease. He was the Founder and co-Director of the Shanghai-Toronto Institute for Health Science (STI), a partnership between the Shanghai Institute of Health Sciences, Shanghai Institute of Organic Chemistry and the University Health Network. UHN currently maintains laboratories in the Zhangjiang High Technology Park in Pudong.

Industry Expertise (5)

Health and Wellness Education/Learning Research Health Care - Services Health Care - Facilities

Areas of Expertise (6)

Immunology Biophysics Lymphocyte Development Antibody Formation Cancer Research Research Management

Education (1)

Cornell University, Graduate School of Medical Sciences: Ph.D., Immunology 1979

Affiliations (6)

  • University of Toronto : Professor, Department of Medical Biophysics and Immunology
  • Terry Fox Research Institute : Board Member
  • The Princess Margaret Cancer Foundation : Board Member
  • Council of Ontario Research Directors : Board Member
  • Ontario Health Research Alliance : Board Member
  • GEMMA Biotechnology : Co-Founder and Chairman

Articles (5)

TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling Genes & Development

1999-01-01

Bone resorption and remodeling is an intricately controlled, physiological process
that requires the function of osteoclasts. The processes governing both the differentiation
and activation of osteoclasts involve signals induced by osteoprotegerin ligand (OPGL), a ...

view more

B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor–derived signals The Journal of Experimental Medicine

1999-01-01

Only mature B lymphocytes can enter the lymphoid follicles of spleen and lymph
nodes and thus efficiently participate in the immune response. Mature, long-lived B
lymphocytes derive from short-lived precursors generated in the bone marrow. We show ...

view more

Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development Cell

1993-01-01

Interferon regulatory factor 1 (IRF-1), a transcriptional activator, and its
antagonistic repressor, IRF-2, were originally identified as regulators of the type I interferon
(IFN) system. We have generated mice deficient in either IRF-1 or IRF-2 by gene targeting ...

view more

CD44 Regulates Hematopoietic Progenitor Distribution, Granuloma Formation, and Tumorigenicity Blood

1997-01-01

CD44 is expressed in various isoforms on numerous cell types and tissues during
embryogenesis and in the mature organism. CD44 may also be involved in tumor growth. To
study the multiple roles of CD44, we abolished expression of all known isoforms of CD44 ...

view more

Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficient mice Cell

1993-01-01

The transmembrane tyrosine phosphatase CD45 is expressed in multiple isoforms
on all nucleated hematopoietic cells, resulting from alternative splicing of variable exons. We
generated mice with a mutation in the variable CD45 exon 6, using homologous ...

view more

Contact